Amgen, Merck, Roche get in on Syapse’s $30M round

Syapse's precision medicine software is already in use at 12 health systems.

Syapse picked up $30 million in series D financing, funds it will use to bring its oncology precision medicine software to more healthcare providers.

In addition to its oncology software platform, which enables caregivers in large health systems to practice precision medicine consistently, Syapse offers a data-sharing network. This provides physicians across the country with real-world data around treatments and outcomes, giving them more evidence on which to base treatment decisions for their patients.

More than 1,000 oncologists at 12 major health systems are already using the software, the San Francisco Business Times reported.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Donald Trump’s healthcare budget outlines FDA, NIH cuts

Amgen Ventures, Medidata Solutions, Merck Global Health Innovation Fund and Roche Venture Fund joined the company’s existing backers in the round, according to a statement. The latter group includes Ascension Ventures, GE Ventures and Intermountain Healthcare Innovation Fund.

Specifically, the San Francisco-based company will use the funds to expand its operations team and offer its precision medicine software at more community health systems. It will also enable Syapse’s customers to increase patient access to clinical trials.

RELATED: VA to use IBM's Watson to ramp up cancer precision medicine

"Precision medicine is transforming cancer care, and to deliver it to patients across the country we need to bring together the many stakeholders across industries," said Syapse CEO Ken Tarkoff. "This funding round does exactly that—helping Syapse and healthcare providers implement large-scale precision oncology programs by uniting a world-class group of healthcare, oncology, technology, and life science leaders.”

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.